Cover Image

TAM receptors Tyro3 and Mer as novel targets in colorectal cancer

CRC remains the third most common cancer worldwide with a high 5-year mortality rate in advanced cases. Combined with chemotherapy, targeted therapy is an additional treatment option. However as CRC still escapes targeted therapy the vigorous search for new targets is warranted to increase patients´...

Full description

Saved in:
Bibliographic Details
Main Authors: Schmitz, Robin (Author) , Freire Valls, Aida (Author) , Yerbes, Rosario (Author) , Richter, Sophie von (Author) , Kahlert, Christoph (Author) , Loges, Sonja (Author) , Weitz, Jürgen (Author) , Schneider, Martin (Author) , Ruiz de Almodóvar, Carmen (Author) , Ulrich, Alexis (Author) , Schmidt, Thomas (Author)
Format: Article (Journal)
Language:English
Published: July 28, 2016
In: OncoTarget
Year: 2016, Volume: 7, Issue: 35, Pages: 56355-56370
ISSN:1949-2553
DOI:10.18632/oncotarget.10889
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.18632/oncotarget.10889
Verlag, lizenzpflichtig, Volltext: https://www.oncotarget.com/article/10889/text/
Get full text
Author Notes:Robin Schmitz, Aida Freire Valls, Rosario Yerbes, Sophie von Richter, Christoph Kahlert, Sonja Loges, Jürgen Weitz, Martin Schneider, Carmen Ruiz de Almodovar, Alexis Ulrich, Thomas Schmidt
Description
Summary:CRC remains the third most common cancer worldwide with a high 5-year mortality rate in advanced cases. Combined with chemotherapy, targeted therapy is an additional treatment option. However as CRC still escapes targeted therapy the vigorous search for new targets is warranted to increase patients´ overall survival.
Item Description:Gesehen am 19.05.2020
Physical Description:Online Resource
ISSN:1949-2553
DOI:10.18632/oncotarget.10889

Similar Items